Body Temperature May Provide Early Warning for Graft-Versus-Host Disease, a Study in Mice Suggests
Proof-of-concept research points to wearable monitors’ potential to offer low-cost, non-invasive way to detect this dangerous bone-marrow transplant complication
Newswise — By continuously monitoring the body temperature of mice that had undergone bone-marrow transplants, researchers were able to detect early warning signs of graft-versus-host disease — a dangerous, sometimes deadly response of the transplanted immune system — in a simple, non-invasive way.
If similar temperature patterns can be detected in human patients, researchers at the University of Michigan are optimistic that wearable temperature monitors could offer a practical, low-cost method for quickly identifying patients who are developing the complication — and thus help to speed interventions and reduce mortality.
“Our study was a proof-of-concept for the hypothesis that temperature fluctuations could give us early indications of the cascading immune response that leads to GVHD,” says study senior author Muneesh Tewari, M.D., Ph.D., a researcher at the U-M Rogel Cancer Center. “We saw changes in the temperature data within the first week after transplantation, which is earlier than what is currently possible for non-invasive detection of GVHD in mice or humans.”
The team’s findings on using temperature monitoring to detect graft-versus-host disease appear in the journal Blood Advances. The research was led by fellows Kuang He, Ph.D., and Hideaki Fujiwara, M.D., Ph.D., and involved a close collaboration between the faculty research groups of Tewari, Zhenke Wu, Ph.D. of the U-M School of Public Health, and Sung Won Choi, M.D. and Pavan Reddy, M.D., of the Medical School.
Bone marrow transplants are a common treatment for cancers including leukemia, lymphoma and myeloma. GVHD occurs when the immune system from the transplant donor sees the recipient’s cells as invaders and attacks them. Up to half of transplant recipients will develop acute GVHD, of which one third will be severe cases, one recent study found.
Biomarkers for graft-versus-host disease have been developed, but predicting GVHD’s onset in individual patients remains imprecise, notes Tewari, a professor of internal medicine at the U-M Medical School, and of biomedical engineering, a joint department of the Medical School and College of Engineering.
The research team used machine learning to detect subtle patterns in the temperature data before obvious trends would be apparent to human observers.
They analyzed hourly temperature readings and, since mice are nocturnal, day-night temperature differences. Both measurements were able to distinguish differences among the mice prone to GVHD within the first four to six days after transplantation.
To extend the research to humans, further study is needed evaluate temperature patterns in human patients, and to better understand potential complicating factors such as variations in room temperature, the presence of infection or the use of medications that can alter body temperature.
The research was supported by funding from the National Institutes of Health, National Cancer Institute (CA046592, CA203542, CA217156), Michigan Precision Health Initiative, Japan Society for the Promotion of Science, YASUDA Medical Foundation, A. Alfred Taubman Medical Research Institute, National Heart, Lung, and Blood Institute (HL128046), Mary Petrovich (through the University of Michigan Fast Forward Gastrointestinal Innovation Fund) and the U-M Frankel Cardiovascular Center’s support for the Physiology Phenotyping Core at U-M.
Additional authors on the paper include Steven Whitesall and Cynthia K. Zajac, both of U-M.
Paper cited: “Computational analysis of continuous body temperature provides early discrimination of graft-versus-host disease in mice,” Blood Advances. DOI: 10.1182/bloodadvances.2019000613